People: ARYx Therapeutics, Inc. (ARYX.O)
2.95USD
9 Feb 2010
$0.02 (+0.68%)
$2.95
--
$3.03
$2.93
42,778
58,607
$6.32
$1.90
Milner, Peter
Brief Biography
Mr. Peter G. Milner, M.D. is President - Research and Development, Director of ARYx Therapeutics Inc. He is co-founder and has served as President, Research and Development, since April 2005. From February 1997 until February 2005, Dr. Milner served as Chief Executive Officer. Dr. Milner is a board certified physician and cardiologist, and serves as voluntary clinical faculty at Stanford Veterans' Hospital. In June 1992, Dr. Milner co-founded CV Therapeutics, Inc., a biopharmaceutical company. Prior to CV Therapeutics, Inc., Dr. Milner was an assistant professor of medicine at Washington University in St. Louis, Missouri. Dr. Milner has numerous patents in his name and is the author of several scientific articles published in peer-reviewed journals. Dr. Milner attended the University of Liverpool, England where he received a bachelor of sciences degree with honors in biochemistry and a degree in medicine. He completed his postgraduate training in medicine at Johns Hopkins Medical School, cardiology and pharmacology at University of Virginia and molecular biology at Washington University in St. Louis. Dr. Milner is a Fellow of the American College of Cardiology, serves on the board of directors of California Healthcare Institute and the Scientific Advisory Board of Novartis Institute of Biomedical Research in Cambridge, Massachusetts.
Basic Compensation
| Total Annual Compensation, USD | Long-Term Incentive Plans, USD | All Other, USD | Fiscal Year Total, USD |
|---|---|---|---|
| 323,294 | -- | 138,595 | 461,889 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
| Goddard, Paul | 856,927 |
| Varian, John | 462,350 |
| Milner, Peter | 461,889 |
| Druzgala, Pascal | 418,194 |
| Nagler, David | 346,752 |
| Canafax, Daniel | 469,475 |





